Search EDSA
Edesa Biotech, Inc.
Nasdaq · CIK 1540159
Last close3.86
Daily change-0.15 (-3.74%)
10 Years gain-99.46%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
EDSA · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 0930
Fundamental
34.9Momentum
n/aAcceleration
n/aConfidence
63.0Annual Revenue9
Quarterly Revenue27
Annual CFO10
Balance SheetMissing
RankingLimited
Score Breakdown
Growth0.0 / 25
Quality18.2 / 25
Capital Efficiency0.0 / 20
Balance Sheet15.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
Gross margin expansionGross margin improved by 4.9752 percentage points.
Key Metrics
Revenue Growth TTM-49.74%OK
Revenue CAGR 3Yn/aINSUFFICIENT_HISTORY
Gross Margin98.66%OK
Operating Marginn/aMISSING
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROICn/aMISSING
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Yn/aINSUFFICIENT_HISTORY
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Sep 30, 2025 | n/a | n/a | -$7.91M | -$7.32M | n/a | n/a | n/a | n/a | -474.73% | n/a |
| 2025 FY Sep 30, 2024 | n/a | n/a | -$7.01M | -$4.89M | n/a | n/a | n/a | n/a | -421.43% | n/a |
| 2024 FY Sep 30, 2023 | n/a | n/a | -$9.22M | -$6.64M | n/a | n/a | n/a | n/a | -368.99% | n/a |
| 2023 FY Sep 30, 2022 | n/a | n/a | -$18.37M | -$12.28M | -$12.28M | n/a | n/a | n/a | -386.01% | n/a |
| 2022 FY Sep 30, 2021 | n/a | n/a | -$23.68M | -$13.66M | -$13.67M | n/a | n/a | n/a | n/a | n/a |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $109,985.00 | sum latest 4 fiscal quarters Revenue | OK | 0001654954-21-008915, 0001654954-21-001660 |
| Revenue Growth TTM | -49.74% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001654954-21-008915, 0001654954-21-001660 |
| Revenue CAGR 3Y | n/a | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | INSUFFICIENT_HISTORY | 0001654954-21-013551 |
| Revenue CAGR 5Y | n/a | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | INSUFFICIENT_HISTORY | 0001654954-21-013551 |
| Gross Profit CAGR 3Y | n/a | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | INSUFFICIENT_HISTORY | 0001654954-21-013551 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 98.66% | Gross Profit / Revenue | OK | 0001654954-21-008915, 0001654954-21-001660 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | derived |
| Current Ratio | 14.58x | Current Assets / Current Liabilities | OK | derived |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |
| Dividend Payout Ratio | n/a | Cash dividends paid / Net income | NOT_MEANINGFUL | derived |
| Diluted EPS TTM | n/a | Net income TTM / Diluted shares | NOT_MEANINGFUL | derived |
| Gross Margin Delta 1Y | +4.98 pp | GrossMargin_current - GrossMargin_prior_year | OK | 0001654954-21-008915, 0001654954-21-001660 |